Catalyst Pharmaceuticals Reports Record Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Portfolio Pulse from
Catalyst Pharmaceuticals reported record financial results for Q4 and full year 2024, with total revenues of $491.7 million, a 23.5% increase year-over-year. The growth was driven by strong sales of FIRDAPSE® and AGAMREE®. The company expects 2025 revenues to be between $545 million and $565 million.
February 26, 2025 | 9:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Catalyst Pharmaceuticals reported record revenues for 2024, with a 23.5% increase driven by FIRDAPSE® and AGAMREE®. The company projects continued growth in 2025 with revenues between $545M and $565M.
The record financial results and strong revenue growth indicate positive business momentum. The projected revenue increase for 2025 suggests continued strong performance, likely boosting investor confidence and positively impacting the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100